Updated:
Vaxcyte
Vaxcyte, co-founded by Grant Pickering in 2013, develops high-valency conjugate vaccines against bacterial diseases from its San Carlos base.
Vaxcyte
Vaxcyte was founded in 2013 by Grant Pickering, a repeat biotech entrepreneur who previously led and sold a vaccine-focused company. The firm raised significant capital through an initial public offering on Nasdaq in 2020 and has since operated as a clinical-stage biotechnology company, not a traditional family office or asset manager. Its sole focus is developing conjugate vaccines using a synthetic platform that avoids culturing live bacteria. The firm's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to cover over 95% of circulating pneumococcal disease strains in adults — a wider net than the market-leading Prevnar 20 from Pfizer. Vaxcyte reported positive topline results from a Phase 3 pivotal non-inferiority study in March 2025, triggering a rapid stock appreciation (per public record). The technology relies on a cell-free protein synthesis system licensed from Sutro Biopharma, enabling the precise placement of antigens and a carrier-sparing architecture intended to boost immune coverage without the dilution-of-efficacy risk seen in some higher-valent competitors. The pipeline also includes VAX-31, a broader-spectrum adult and pediatric candidate, and VAX-A1, a prophylactic for Group A Strep. Vaxcyte's operations center in San Carlos, California. As of early 2025, the firm carried no debt and held over $3 billion in cash and equivalents following a public offering in early 2025, a balance intended to fully fund operations through at least 2027 (per the firm, Q1 2025). Grant Pickering leads the company as CEO and co-founder alongside biochemist Jeff Fairman, who serves as Vice President of Research. The board includes experienced operators from Gilead, Genentech, and Novartis. In March 2025, Vaxcyte announced the retirement of longtime board member and former Gilead CSO Norbert Bischofberger, while simultaneously promoting internal clinical leadership to prepare for potential U.S. biologics license applications. Vaxcyte's structural differentiator is its spectrum ambition. While Pfizer and Merck dominate the pneumococcal conjugate market with vaccines covering up to 21 serotypes, Vaxcyte's platform targets 24 to 31 serotypes without sacrificing immunogenicity. The manufacturing model — cell-free and modular — decouples production scale from bacterial growth limits, positioning it as a platform flexible enough to expand beyond pneumococcal disease into other bacterial pathogens with high unmet need.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Carlos
Corporate office
San Carlos, CA, United States
Principals
Grant Pickering
Chief Executive Officer and Co-Founder
Sector focus
Frequently asked questions
What is Vaxcyte's lead program and its clinical status?
VAX-24, a 24-valent pneumococcal conjugate vaccine, is the lead candidate. In March 2025, the firm reported positive results from a pivotal Phase 3 non-inferiority study in adults, meeting all primary endpoints (per public record). A supplemental pipeline candidate, VAX-31, targets an even broader set of serotypes and is in Phase 2 trials for both adults and infants.
How does Vaxcyte's platform differ from traditional vaccine manufacturing?
Vaxcyte uses a cell-free protein synthesis platform that produces antigens without culturing live bacteria, a license from Sutro Biopharma. This allows precise control over antigen structure and attachment chemistry, enabling the construction of higher-valency vaccines without the manufacturing bottlenecks and immunogenicity trade-offs common in whole-cell or live-pathogen approaches.
Who runs investment decisions at Vaxcyte?
Vaxcyte is a publicly traded biotechnology company with no centralized investment portfolio. Capital allocation decisions are made by the executive leadership team led by CEO and co-founder Grant Pickering, with board oversight. The board includes experienced biopharma operators and investors, including representatives from leading venture and institutional firms that backed the company pre-IPO.
What is the balance-sheet position of Vaxcyte?
As of early 2025, Vaxcyte holds over $3 billion in cash and equivalents with zero outstanding debt, following a public equity raise. The firm states this provides a cash runway through at least 2027, intended to fund pivotal trials, pipeline expansion, and initial commercial build-out without need for additional financing.
Which pathogens does Vaxcyte target beyond pneumococcal disease?
Beyond the pneumococcal programs VAX-24 and VAX-31, Vaxcyte is developing VAX-A1, a prophylactic vaccine candidate against Group A Streptococcus. The firm's platform is theoretically extensible to other bacterial pathogens where a conjugate approach is biologically relevant, but pneumococcal disease remains the primary near-term commercial focus.
Who founded Vaxcyte and what is the management's background?
Grant Pickering and Jeff Fairman co-founded the company in 2013. Pickering previously founded and sold a vaccine biotech, while Fairman, a biochemist, serves as VP of Research. The board and leadership include former senior executives from Gilead, Genentech, and Novartis, lending substantial vaccine and biologics development expertise.
Is Vaxcyte structured as a family office or an operating company?
Vaxcyte is an operating company — specifically, a clinical-stage public biotechnology firm — not a family office or investment vehicle. It employs scientists, clinical operations staff, and regulatory professionals to develop its own proprietary vaccine candidates. Its market capitalization and cash holdings reflect its status as an operating entity, not assets under management for third-party capital.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: